2025-06-14 05:05:01
Latest Post
ITC acquires shares of Sresta Natural Bioproducts Private Limited
Syngene International Ltd updates on USFDA inspection at Biocon Park, SEZ, Bengaluru
NTPC declares commercial operation of Unit 3 of North Karanpura Super Thermal Power Project
EPACK Durable Ltd awarded 'Best Overall Product' at Global LEAP Awards
IOL Chemicals and Pharmaceuticals Ltd registers Acetic Anhydride with REACH
Stock Report
Bliss GVS Pharma Ltd posts consolidated PAT of Rs. 15.53 crores in Q4FY25
Posted On : 2025-05-12 22:39:44( TIMEZONE : IST )
Bliss GVS Pharma Limited has reported Consolidated financial results for the period ended March 31, 2025.
Financial Results (Q4 FY2025) - QoQ Comparison
The company has reported total income of Rs. 210.0543 crores during the period ended March 31, 2025 as compared to Rs. 225.6833 crores during the period ended December 31, 2024.
The company has posted net profit / (loss) of Rs. 15.5391 crores for the period ended March 31, 2025 as against net profit / (loss) of Rs. 23.8024 crores for the period ended December 31, 2024.
The company has reported EPS of Rs. 1.46 for the period ended March 31, 2025 as compared to Rs. 2.27 for the period ended December 31, 2024.
| Financials | Q4 FY2025 | Q3 FY2025 | % Change |
| Total Income | ₹ 210.0543 crs | ₹225.6833 crs |  -6.93% |
| Net Profit | ₹15.5391 crs | ₹23.8024 crs | -34.72% |
| EPS | ₹1.46 | ₹2.27 | -35.68% |
Financial Results (Q4 FY2025) - YoY Comparison
The company has reported total income of Rs. 210.0543 crores during the period ended March 31, 2025 as compared to Rs.203.7278 crores during the period ended March 31, 2024.
The company has posted net profit / (loss) of Rs.15.5391 crores for the period ended March 31, 2025 as against net profit / (loss) of Rs.-9.1477 crores for the period ended March 31, 2024.
The company has reported EPS of Rs.1.46 for the period ended March 31, 2025 as compared to Rs.-0.86 for the period ended March 31, 2024.
| Financials | Q4 FY2025 | Q4 FY2024 | % Change |
| Total Income | ₹ 210.0543 crs | ₹203.7278 crs |  3.11% |
| Net Profit | ₹15.5391 crs | ₹-9.1477 crs | 269.87% |
| EPS | ₹1.46 | ₹-0.86 | 269.77% |
Financial Results (Year Ended FY2025) - YoY Comparison
The company has reported total income of Rs.846.2197 crores during the Financial Year ended March 31, 2025 as compared to Rs.798.9823 crores during the Financial Year ended March 31, 2024.
The company has posted net profit / (loss) of Rs.84.2993 crores for the Financial Year ended March 31, 2025 as against net profit / (loss) of Rs.75.4541 crores for the Financial Year ended March 31, 2024.
The company has reported EPS of Rs.7.95 for the Financial Year ended March 31, 2025 as compared to Rs.7.11 for the Financial Year ended March 31, 2024.
| Financials | Year Ended FY2025 | Year Ended FY2024 | % Change |
| Total Income | ₹846.2197 crs | ₹798.9823 crs | 5.91% |
| Net Profit | ₹84.2993 crs | ₹75.4541 crs | 11.72% |
| EPS | ₹7.95 | ₹7.11 | 11.81% |
Shares of Bliss GVS Pharma Limited was last trading in BSE at Rs. 118.75 as compared to the previous close of Rs. 112.05. The total number of shares traded during the day was 30546 in over 451 trades.
The stock hit an intraday high of Rs. 119.65 and intraday low of 115.30. The net turnover during the day was Rs. 3590634.00.
